title: Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data.
abstract: OBJECTIVE
  The Japanese blood glucose monitoring guidance for patients receiving second-generation antipsychotics has been newly developed. We aimed to report a cross-sectional study using the baseline data of the Japanese monitoring guidance to find undiagnosed hyperglycemia systematically as a routine clinical practice and to quantify the frequency of glucose abnormalities in schizophrenia patients treated with second-generation antipsychotics.
  
  
  METHODS
  Data for 537 patients with schizophrenia, who had not been diagnosed as having diabetes prior to baseline screening and started the monitoring between June 2008 and January 2009, were collected from medical records in 25 hospitals. Blood glucose (fasting or casual), hemoglobin(A1c) , serum lipids, height/weight, clinical diabetic symptoms, and family history of diabetes were assessed. Patients were classified into normal, pre-diabetic or probable diabetic type based on their values of blood glucose or hemoglobin(A1c) , and various background characteristics and serum lipid values were compared among the three types.
  
  
  RESULTS
  Out of 537 patients, 13 (2.4%) met criteria for probable diabetic type, 51 (9.5%) for pre-diabetic type, and 473 (88.1%) for normal type. Individuals categorized as probable diabetic type had a higher body mass index and higher frequency of family history of diabetes mellitus than those with normal type.
  
  
  CONCLUSIONS
  Glucose abnormalities were newly detected in 11.9% of schizophrenia patients treated with second-generation antipsychotics by the baseline monitoring. To assess the detective power and usefulness of the guidance, longitudinal investigations are necessary.
authors.affiliation: Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan. ikusumi@med.hokudai.ac.jp
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kusumi
authors.forename: Koki
authors.initials: K
authors.lastname: Ito
authors.forename: Minoru
authors.initials: M
authors.lastname: Honda
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Hayashishita
authors.forename: Keiichi
authors.initials: K
authors.lastname: Uemura
authors.forename: Naoki
authors.initials: N
authors.lastname: Hashimoto
authors.forename: Mitsukuni
authors.initials: M
authors.lastname: Murasaki
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Atsumi
authors.forename: Takashi
authors.initials: T
authors.lastname: Kadowaki
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Koyama
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D044466:Asian People; D001786:Blood Glucose; D015190:Blood Glucose Self-Monitoring; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000175:diagnosis* / Q000209:etiology; D005260:Female; D006442:Glycated Hemoglobin; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D006442:Glycated Hemoglobin